The global insulin-like growth factor II market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of chronic diseases such as cancer and diabetes, which are major drivers for the insulin-like growth factor II market. Insulin-like growth factor II has been found to be effective in treating various types of cancers such as breast cancer and hormone sensitive breast cancer, Huntington disease, and muscular dystrophy. Insulin-like growth factor II also helps in reducing the risk of developing type 2 diabetes by regulating blood sugar levels in patients with type 1 diabetes mellitus or type 2 diabetes mellitus.
Some Of The Growth Factors Of This Market:
- Insulin-like growth factor II has been found to be an important regulator of glucose metabolism and lipid metabolism in humans and animals alike; hence it is used for treating metabolic disorders such as diabetes mellitus type 2 and obesity which are major drivers for the insulin-like growth factor II market globally.
- Insulin-like growth factor II has also been found to be effective in treating osteoporosis which is another major driver for the global insulin-like growth factor II market due to its ability in stimulating bone formation and inhibiting bone resorption thereby improving bone mineral density (BMD).
Industry Growth Insights published a new data on “Insulin Like Growth Factor II Market”. The research report is titled “Insulin Like Growth Factor II Market research by Types (Dusigitumab, M-630, GM-6, M-610.27, Xentuzumab, Others), By Applications (Breast Cancer, Hormone Sensitive Breast Cancer, Huntington Disease, Muscular Dystrophy, Others), By Players/Companies Boehringer Ingelheim GmbH, Genervon Biopharmaceuticals LLC, MedImmune LLC, ...”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Insulin Like Growth Factor II Market Research Report
By Type
Dusigitumab, M-630, GM-6, M-610.27, Xentuzumab, Others
By Application
Breast Cancer, Hormone Sensitive Breast Cancer, Huntington Disease, Muscular Dystrophy, Others
By Companies
Boehringer Ingelheim GmbH, Genervon Biopharmaceuticals LLC, MedImmune LLC, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Insulin Like Growth Factor II Market Report Segments:
The global Insulin Like Growth Factor II market is segmented on the basis of:
Types
Dusigitumab, M-630, GM-6, M-610.27, Xentuzumab, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Breast Cancer, Hormone Sensitive Breast Cancer, Huntington Disease, Muscular Dystrophy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boehringer Ingelheim GmbH
- Genervon Biopharmaceuticals LLC
- MedImmune LLC
- ...
Highlights of The Insulin Like Growth Factor II Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Dusigitumab
- M-630
- GM-6
- M-610.27
- Xentuzumab
- Others
- By Application:
- Breast Cancer
- Hormone Sensitive Breast Cancer
- Huntington Disease
- Muscular Dystrophy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Insulin Like Growth Factor II Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Insulin like growth factor II (IGF-II) is a hormone that helps to promote the growth of cells in the body. IGF-II is produced by the liver and it plays a role in energy production and cell survival.
Some of the key players operating in the insulin like growth factor ii market are Boehringer Ingelheim GmbH, Genervon Biopharmaceuticals LLC, MedImmune LLC.
The insulin like growth factor ii market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Insulin Like Growth Factor II Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Insulin Like Growth Factor II Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Insulin Like Growth Factor II Market - Supply Chain
4.5. Global Insulin Like Growth Factor II Market Forecast
4.5.1. Insulin Like Growth Factor II Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Insulin Like Growth Factor II Market Size (000 Units) and Y-o-Y Growth
4.5.3. Insulin Like Growth Factor II Market Absolute $ Opportunity
5. Global Insulin Like Growth Factor II Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Insulin Like Growth Factor II Market Size and Volume Forecast by Type
5.3.1. Dusigitumab
5.3.2. M-630
5.3.3. GM-6
5.3.4. M-610.27
5.3.5. Xentuzumab
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Insulin Like Growth Factor II Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Insulin Like Growth Factor II Market Size and Volume Forecast by Application
6.3.1. Breast Cancer
6.3.2. Hormone Sensitive Breast Cancer
6.3.3. Huntington Disease
6.3.4. Muscular Dystrophy
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Insulin Like Growth Factor II Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Insulin Like Growth Factor II Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Insulin Like Growth Factor II Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Insulin Like Growth Factor II Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Insulin Like Growth Factor II Demand Share Forecast, 2019-2029
9. North America Insulin Like Growth Factor II Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Insulin Like Growth Factor II Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Insulin Like Growth Factor II Market Size and Volume Forecast by Application
9.4.1. Breast Cancer
9.4.2. Hormone Sensitive Breast Cancer
9.4.3. Huntington Disease
9.4.4. Muscular Dystrophy
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Insulin Like Growth Factor II Market Size and Volume Forecast by Type
9.7.1. Dusigitumab
9.7.2. M-630
9.7.3. GM-6
9.7.4. M-610.27
9.7.5. Xentuzumab
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Insulin Like Growth Factor II Demand Share Forecast, 2019-2029
10. Latin America Insulin Like Growth Factor II Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Insulin Like Growth Factor II Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Insulin Like Growth Factor II Market Size and Volume Forecast by Application
10.4.1. Breast Cancer
10.4.2. Hormone Sensitive Breast Cancer
10.4.3. Huntington Disease
10.4.4. Muscular Dystrophy
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Insulin Like Growth Factor II Market Size and Volume Forecast by Type
10.7.1. Dusigitumab
10.7.2. M-630
10.7.3. GM-6
10.7.4. M-610.27
10.7.5. Xentuzumab
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Insulin Like Growth Factor II Demand Share Forecast, 2019-2029
11. Europe Insulin Like Growth Factor II Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Insulin Like Growth Factor II Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Insulin Like Growth Factor II Market Size and Volume Forecast by Application
11.4.1. Breast Cancer
11.4.2. Hormone Sensitive Breast Cancer
11.4.3. Huntington Disease
11.4.4. Muscular Dystrophy
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Insulin Like Growth Factor II Market Size and Volume Forecast by Type
11.7.1. Dusigitumab
11.7.2. M-630
11.7.3. GM-6
11.7.4. M-610.27
11.7.5. Xentuzumab
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Insulin Like Growth Factor II Demand Share, 2019-2029
12. Asia Pacific Insulin Like Growth Factor II Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Insulin Like Growth Factor II Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Insulin Like Growth Factor II Market Size and Volume Forecast by Application
12.4.1. Breast Cancer
12.4.2. Hormone Sensitive Breast Cancer
12.4.3. Huntington Disease
12.4.4. Muscular Dystrophy
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Insulin Like Growth Factor II Market Size and Volume Forecast by Type
12.7.1. Dusigitumab
12.7.2. M-630
12.7.3. GM-6
12.7.4. M-610.27
12.7.5. Xentuzumab
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Insulin Like Growth Factor II Demand Share, 2019-2029
13. Middle East & Africa Insulin Like Growth Factor II Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Insulin Like Growth Factor II Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Insulin Like Growth Factor II Market Size and Volume Forecast by Application
13.4.1. Breast Cancer
13.4.2. Hormone Sensitive Breast Cancer
13.4.3. Huntington Disease
13.4.4. Muscular Dystrophy
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Insulin Like Growth Factor II Market Size and Volume Forecast by Type
13.7.1. Dusigitumab
13.7.2. M-630
13.7.3. GM-6
13.7.4. M-610.27
13.7.5. Xentuzumab
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Insulin Like Growth Factor II Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Insulin Like Growth Factor II Market: Market Share Analysis
14.2. Insulin Like Growth Factor II Distributors and Customers
14.3. Insulin Like Growth Factor II Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Boehringer Ingelheim GmbH
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Genervon Biopharmaceuticals LLC
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. MedImmune LLC
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. ...
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
